<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">AIDS</journal-id>
      <journal-id journal-id-type="iso-abbrev">AIDS</journal-id>
      <journal-id journal-id-type="publisher-id">AIDS</journal-id>
      <journal-title-group>
        <journal-title>AIDS (London, England)</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0269-9370</issn>
      <issn pub-type="epub">1473-5571</issn>
      <publisher>
        <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25909831</article-id>
      <article-id pub-id-type="pmc">4444421</article-id>
      <article-id pub-id-type="doi">10.1097/QAD.0000000000000621</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Correspondence</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Apparent spontaneous clearance of chronic hepatitis C virus infection in a HIV co-infected patient with decompensated cirrhosis: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Mora-Peris</surname>
            <given-names>Borja</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>b</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Goldin</surname>
            <given-names>Robert D.</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>c</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Muir</surname>
            <given-names>David</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>d</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Main</surname>
            <given-names>Janice</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>b</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gellissen</surname>
            <given-names>Ricky</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>b</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brown</surname>
            <given-names>Anthony</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>e</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barnes</surname>
            <given-names>Eleanor</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>e</sup>
          </xref>
          <xref ref-type="aff" rid="aff6">
            <sup>f</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cooke</surname>
            <given-names>Graham</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>b</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>a</label>Department of Medicine, Faculty of Medicine, Imperial College London, St Mary's Hospital Campus, Norfolk Place</aff>
      <aff id="aff2"><label>b</label>Department of HIV and Genitourinary Medicine</aff>
      <aff id="aff3"><label>c</label>Department of Cellular Pathology, Imperial College Healthcare NHS Trust, St Mary's Hospital</aff>
      <aff id="aff4"><label>d</label>Department of Infection &amp; Immunity, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London</aff>
      <aff id="aff5"><label>e</label>Peter Medawar Building for Pathogen Research, Oxford University</aff>
      <aff id="aff6"><label>f</label>NIHR Oxford Biomedical Research Centre, Oxford, UK.</aff>
      <author-notes>
        <corresp>Correspondence to Dr Borja Mora-Peris, Clinical Trials, Winston Churchill Wing, St Mary's Hospital, Imperial College London, Praed Street, London W2 1NY, <country>UK</country>. Tel: +44 203 312 6789; fax: +44 203 312 6123; e-mail: <email>b.mora-peris@imperial.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>15</day>
        <month>5</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>06</day>
        <month>5</month>
        <year>2015</year>
      </pub-date>
      <volume>29</volume>
      <issue>8</issue>
      <fpage>982</fpage>
      <lpage>985</lpage>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>1</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>30</day>
          <month>1</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>09</day>
          <month>2</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2015 Wolters Kluwer Health, Inc. All rights reserved.</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0">
          <license-p>This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link></license-p>
        </license>
      </permissions>
      <self-uri xlink:type="simple" xlink:href="aids-29-982.pdf"/>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Spontaneous clearance of chronic hepatitis C virus (HCV) infection is unusual, once chronic disease is established, particularly in HIV/HCV co-infected individuals [<xref rid="R1" ref-type="bibr">1</xref>]. In cirrhotic patients, pegylated interferon-based regimens achieve lower sustained virological response (SVR) rates and increase the likelihood of decompensation [<xref rid="R2" ref-type="bibr">2</xref>]. However, interferon-sparing regimens using novel direct-acting antivirals (DAAs) are now becoming available and have dramatically increased the SVR rates among cirrhotic patients, minimizing the risk of hepatic decompensation [<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref>].</p>
    <p>We report a patient with HIV/HCV co-infection and decompensated cirrhosis who appeared to have cleared HCV spontaneously on intensive investigation and, therefore, was not offered interferon-free treatment.</p>
    <p>A 43-year-old heterosexual man with a history of prior intravenous drug use was initially diagnosed with HIV-1 infection in 2008 in the context of <italic>Pneumocystis jirovecii</italic> pneumonia. At baseline, he had a CD4<sup>+</sup> cell count of 30&#x200A;cells/&#x3BC;l, plasma HIV RNA of 39&#x200A;911&#x200A;copies/ml, positive anti-HCV (Abbott Architect; Abbott Diagnostics, Abbott Park, Illinois, USA) and confirmed HCV genotype 4 infection by sequencing (Micropathology Ltd, Coventry, UK) with a plasma HCV RNA level of 602&#x200A;745&#x200A;IU/ml (Abbott Real Time HCV PCR, M2000 system; Abbott Diagnostics). He was later shown to be IL28B-CC genotype. Screening demonstrated past hepatitis B virus (HBV) infection with negative surface antigen and undetectable HBV DNA. Combination antiretroviral therapy (cART) with emtricitabine/tenofovir/efavirenz (200/300/600&#x200A;mg) once daily was initiated shortly after HIV diagnosis and, by 1 year of treatment, his CD4<sup>+</sup> cell count had improved to 310&#x200A;cells/&#x3BC;l. Soon afterwards, he developed decompensation of his chronic liver infection in the form of ascites, jaundice and mild encephalopathy (Child&#x2013;Pugh B). A liver biopsy showed florid periportal bile duct reaction, marked lobular inflammation and fibrosis scoring 4/6. A decision for HCV treatment was deferred whilst the patient attempted to reduce his high BMI. Regular alpha-fetoprotein levels, liver ultrasound and MRI scans were performed without evidence of hepatocellular carcinoma.</p>
    <p>His cirrhosis progressed to Child&#x2013;Pugh C and the patient was referred for liver transplantation, which was turned down due to a low predicted 5-year survival, an assessment influenced by the patient's refusal to receive blood products according to his beliefs as a Jehovah's witness.</p>
    <p>His liver function deteriorated further despite medical management. To minimize drug interactions in case of transplantation and/or HCV treatment, efavirenz was switched to raltegravir 400&#x200A;mg twice daily in January 2013. Around that time, plasma HCV RNA levels experienced a downward trend, achieving values of less than 15 HCV RNA IU/ml (Roche Cobas TaqMan; Roche Molecular Diagnostics, Pleasanton, California, USA) in January 2014. At that time, he was considered for early access to DAA therapy (sofosbuvir with either ledipasvir or daclatasvir). Subsequently, no HCV RNA was detected on three occasions (February, April and June 2014). In parallel, CD4<sup>+</sup> cell count increased from 370&#x200A;cells/ml (21%) in April 2012, to 955&#x200A;cells/ml (31%) in June 2014 (Fig. <xref ref-type="fig" rid="F1">1</xref>).</p>
    <fig id="F1" position="float">
      <label>Fig. 1</label>
      <caption>
        <p>Time trends from HIV presentation in May 2008 for antiretroviral regimes (with fixed nuke-backbone maintained throughout regimes) and laboratory results: ALT, HCV RNA, HIV RNA, absolute CD4<sup>+</sup> cell count and CD4<sup>+</sup> percentage.</p>
      </caption>
      <graphic xlink:href="aids-29-982-g001"/>
      <p>ALT, alanine transaminase; cART, combined antiretroviral therapy; DRV/r, darunavir/ritonavir; EFV, efavirenz; FTC, emtricitabine; HCV, hepatitis C virus; RAL, raltegravir; RNA, ribonucleic acid; and TDF, tenofovir.</p>
    </fig>
    <p>A transjugular liver biopsy was performed showing evidence of inactive cirrhosis, mild portal and nodular inflammation, no large cell or fatty change, negative stains for iron and alpha-1 antitrypsin consistent with resolved infection and no evidence of HCV RNA on PCR (Micropathology Ltd). An HCV-specific enzyme-linked ImmunoSpot that assessed interferon-&#x3B3; production in peripheral blood mononuclear cells (stimulated by gt1 and gt4 HCV peptides) at this time was not reactive, suggesting recovery of CD8<sup>+</sup> and CD4<sup>+</sup> T-cell immunity was not responsible for his HCV clearance.</p>
    <p>Spontaneous clearances of established HCV infection have been previously described in absence of specific anti-HCV CD4<sup>+</sup> responses [<xref rid="R5" ref-type="bibr">5</xref>]. Although rare, HCV clearance among HIV&#x2013;HCV co-infected patients on cART is mainly described in patients with IL-28B CC genotype, suggesting this subset of patients might benefit from an earlier initiation of cART [<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R6" ref-type="bibr">6</xref>&#x2013;<xref rid="R9" ref-type="bibr">9</xref>]. The initial period of HCV undetectability coincided with a switch to raltegravir and a marked increase in peripheral CD4<sup>+</sup> cell count. Whether this was causal is unclear. However, maintained HIV viral suppression [<xref rid="R10" ref-type="bibr">10</xref>] and improvements in drug-associated hepatotoxicity have been described in cirrhotic HCV&#x2013;HIV co-infected patients after switching to raltegravir [<xref rid="R11" ref-type="bibr">11</xref>].</p>
    <p>What makes this case more unusual is that, given the potential availability of novel DAAs to a limited number of patients, invasive liver investigation was undertaken, which not only failed to find virus, but also showed little evidence of active infection. Cases such as this one raise important implications for patients with very advanced disease being considered for DAA therapy. The potential for low-level viraemia, and even prolonged periods of aviraemia, is well recognized [<xref rid="R12" ref-type="bibr">12</xref>]. Whether in these patients more invasive investigations are helpful to exclude the possibility for a hidden focus of HCV infection is unclear. It remains uncertain as to whether, in the absence of viraemia, the likelihood of persistent viral reservoirs should be sufficient to justify treatment.</p>
    <sec>
      <title>Acknowledgements</title>
      <p>The authors would like to thank the patient, as well as the nursing and pharmacy staff at the Department of HIV and Genitourinary Medicine at St Mary's Hospital (Imperial College Healthcare NHS Trust, London, UK). This work was supported in part by the BRC of Imperial College NHS Trust. EB and GC are supported are part of the MRC STOP HCV and NHIC consortia.</p>
      <sec>
        <title>Conflicts of interest</title>
        <p>There are no conflicts of interest.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stenkvist</surname><given-names>J</given-names></name><name><surname>Nystr&#xF6;m</surname><given-names>J</given-names></name><name><surname>Falconer</surname><given-names>K</given-names></name><name><surname>S&#xF6;nnerborg</surname><given-names>A</given-names></name><name><surname>Weiland</surname><given-names>O</given-names></name></person-group>
<article-title>Occasional spontaneous clearance of chronic hepatitis C virus in HIV infected individuals</article-title>. <source><italic>J Hepatol</italic></source>
<year>2014</year>; <volume>61</volume>:<fpage>957</fpage>&#x2013;<lpage>961</lpage>.<pub-id pub-id-type="pmid">24951853</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruno</surname><given-names>S</given-names></name><name><surname>Shiffman</surname><given-names>ML</given-names></name><name><surname>Roberts</surname><given-names>SK</given-names></name><name><surname>Gane</surname><given-names>EJ</given-names></name><name><surname>Messinger</surname><given-names>D</given-names></name><name><surname>Hadziyannis</surname><given-names>SJ</given-names></name><name><surname>Marcellin</surname><given-names>P</given-names></name></person-group>
<article-title>Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis</article-title>. <source><italic>Hepatology</italic></source>
<year>2010</year>; <volume>51</volume>:<fpage>388</fpage>&#x2013;<lpage>397</lpage>.<pub-id pub-id-type="pmid">19918980</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawitz</surname><given-names>E</given-names></name><name><surname>Mangia</surname><given-names>A</given-names></name><name><surname>Wyles</surname><given-names>D</given-names></name><name><surname>Rodriguez-Torres</surname><given-names>M</given-names></name><name><surname>Hassanein</surname><given-names>T</given-names></name><name><surname>Gordon</surname><given-names>SC</given-names></name></person-group>
<article-title>Sofosbuvir for previously untreated chronic hepatitis C infection</article-title>. <source><italic>N Engl J Med</italic></source>
<year>2013</year>; <volume>368</volume>:<fpage>1878</fpage>&#x2013;<lpage>1887</lpage>.<pub-id pub-id-type="pmid">23607594</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Lawitz</surname><given-names>E</given-names></name><name><surname>Ghalib</surname><given-names>R</given-names></name><name><surname>Rodriguez-Torres</surname><given-names>M</given-names></name><name><surname>Younossi</surname><given-names>Z</given-names></name><name><surname>Corregidor</surname><given-names>A</given-names></name><name><surname>Jacobson</surname><given-names>I</given-names></name></person-group>
<article-title>Suppression of viral load through 4 weeks posttreatment results of a once-daily regimen of simeprevir&#x200A;+&#x200A;sofosbuvir with or without ribavirin in hepatitis C virus GT 1 null responders</article-title>. <conf-name>20th Conference on Retroviruses and Opportunistic Infections 2013</conf-name>
<comment>[Abstract 155LB]</comment>.</mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potthoff</surname><given-names>A</given-names></name><name><surname>Sarhaddar</surname><given-names>J</given-names></name><name><surname>Wiegand</surname><given-names>J</given-names></name><name><surname>Lichtinghagen</surname><given-names>R</given-names></name><name><surname>Sarrazin</surname><given-names>C</given-names></name><name><surname>Ciner</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Spontaneous resolution of chronic hepatitis C virus infection after antiviral treatment and relapse</article-title>. <source><italic>Hepatol Res</italic></source>
<year>2005</year>; <volume>31</volume>:<fpage>18</fpage>&#x2013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">15652466</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vispo</surname><given-names>E</given-names></name><name><surname>Barreiro</surname><given-names>P</given-names></name><name><surname>Plaza</surname><given-names>Z</given-names></name><name><surname>Fern&#xE1;ndez-Montero</surname><given-names>JV</given-names></name><name><surname>Labarga</surname><given-names>P</given-names></name><name><surname>de Mendoza</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy</article-title>. <source><italic>AIDS</italic></source>
<year>2014</year>; <volume>28</volume>:<fpage>1473</fpage>&#x2013;<lpage>1478</lpage>.<pub-id pub-id-type="pmid">24637541</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>D</given-names></name><name><surname>Fellay</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>AJ</given-names></name><name><surname>Simon</surname><given-names>JS</given-names></name><name><surname>Shianna</surname><given-names>KV</given-names></name><name><surname>Urban</surname><given-names>TJ</given-names></name><etal/></person-group>
<article-title>Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance</article-title>. <source><italic>Nature</italic></source>
<year>2009</year>; <volume>461</volume>:<fpage>399</fpage>&#x2013;<lpage>401</lpage>.<pub-id pub-id-type="pmid">19684573</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#xE9;rez-Olmeda</surname><given-names>M</given-names></name><name><surname>Garc&#xED;a-Samaniego</surname><given-names>J</given-names></name><name><surname>Soriano</surname><given-names>V</given-names></name></person-group>
<article-title>Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy</article-title>. <source><italic>AIDS</italic></source>
<year>2000</year>; <volume>14</volume>:<fpage>212</fpage>.<pub-id pub-id-type="pmid">10708298</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>CL</given-names></name><name><surname>Cameron</surname><given-names>DW</given-names></name></person-group>
<article-title>Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection</article-title>. <source><italic>Clin Infect Dis</italic></source>
<year>2002</year>; <volume>35</volume>:<fpage>873</fpage>&#x2013;<lpage>879</lpage>.<pub-id pub-id-type="pmid">12228825</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hern&#xE1;ndez-Novoa</surname><given-names>B</given-names></name><name><surname>Moreno</surname><given-names>A</given-names></name><name><surname>P&#xE9;rez-El&#xED;as</surname><given-names>MJ</given-names></name><name><surname>Quereda</surname><given-names>C</given-names></name><name><surname>Dronda</surname><given-names>F</given-names></name><name><surname>Casado</surname><given-names>JL</given-names></name><etal/></person-group>
<article-title>Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C)</article-title>. <source><italic>J Antimicrob Chemother</italic></source>
<year>2014</year>; <volume>69</volume>:<fpage>471</fpage>&#x2013;<lpage>475</lpage>.<pub-id pub-id-type="pmid">24097843</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cevik</surname><given-names>M</given-names></name><name><surname>Katsarolis</surname><given-names>I</given-names></name><name><surname>Singh</surname><given-names>GJ</given-names></name><name><surname>Nelson</surname><given-names>M</given-names></name></person-group>
<article-title>A switch to Raltegravir improves antiretroviral associated hepatotoxicity in individuals co-infected with HIV and hepatitis C</article-title>. <source><italic>J Infect</italic></source>
<year>2014</year>; <volume>69</volume>:<fpage>190</fpage>&#x2013;<lpage>193</lpage>.<pub-id pub-id-type="pmid">24793307</pub-id></mixed-citation>
      </ref>
      <ref id="R12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidimliski</surname><given-names>PD</given-names></name><name><surname>Nikolov</surname><given-names>I</given-names></name><name><surname>Geshkovska</surname><given-names>NM</given-names></name><name><surname>Dimovski</surname><given-names>A</given-names></name><name><surname>Rostaing</surname><given-names>L</given-names></name><name><surname>Sikole</surname><given-names>A</given-names></name></person-group>
<article-title>Review: Occult hepatitis C virus infection: still remains a controversy</article-title>. <source><italic>J Med Virol</italic></source>
<year>2014</year>; <volume>86</volume>:<fpage>1491</fpage>&#x2013;<lpage>1498</lpage>.<pub-id pub-id-type="pmid">24895180</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
